|1.||Pascal, M: 1 article (10/2000)|
|2.||Rivera, F: 1 article (10/2000)|
|3.||Morales-Ruiz, M: 1 article (10/2000)|
|4.||Maffrand, J P: 1 article (10/2000)|
|5.||Ros, J: 1 article (10/2000)|
|6.||Cejudo, P: 1 article (10/2000)|
|7.||Gal, C S: 1 article (10/2000)|
|8.||Arroyo, V: 1 article (10/2000)|
|9.||Jiménez, W: 1 article (10/2000)|
|10.||Cano, C: 1 article (10/2000)|
01/01/2000 - "This study shows that niravoline administration induces an aquaretic response and is well tolerated, at moderate doses, in patients with cirrhosis. "
01/01/2000 - "The aim of this study was to evaluate the aquaretic effect and tolerance of niravoline in patients with cirrhosis. "
09/01/1996 - "Thus, the present study examined the effects of niravoline on renal function in rats with cirrhosis. "
01/01/2000 - "Thus, moderate doses of niravoline may be useful for treating patients with cirrhosis and water retention."
01/01/2000 - "Biochemical tests and hemodynamic values were determined before and 1, 2, 3 and 24 h after niravoline administration at doses ranging from 0.5 to 2 mg iv in 18 patients with cirrhosis. "
02/01/2000 - "The results from this present study provide further evidence that niravoline is effective in reducing elevated intracranial pressure, brain water content, and maintaining an adequate cerebral perfusion pressure even in the presence of an extradural mass lesion. "
01/01/1997 - "RU 51599, a selective kappa opioid agonist which is a potent aquaretic, was studied for its effect on acute intracranial hypertension. "
01/01/1997 - "Treatment of acute intracranial hypertension with RU 51599, a selective kappa opioid agonist."
02/01/2000 - "Niravoline, a selective kappa-opioid receptor agonist effectively reduces elevated intracranial pressure."
02/01/2000 - "To ascertain the effects of niravoline (RU 51599, a selective kappa-opioid receptor agonist) on elevated intracranial pressure with mass lesion, the authors experimentally induced intracranial hypertension in cats by progressive inflation of an extradural balloon with physiological saline at the constant rate of 0.5 ml/h for 2.5 h. "
07/01/1995 - "Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention."
10/01/1997 - "The development of niravoline as an aquaretic for the treatment of cirrhosis with ascites and other hyponatraemic disorders has also been halted. "
07/01/1995 - "The aim of this study was to evaluate the aquaretic efficacy of the kappa-opioid receptor agonist RU 51599 in conscious cirrhotic rats with ascites and water retention. "
04/01/1999 - "Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention."
04/01/1999 - "Therefore, both agents have aquaretic efficacy, but the beneficial therapeutic effects of the long-term oral administration of niravoline are more consistent than those of OPC-31260 in cirrhotic rats with ascites and water retention."
|1.||kappa Opioid Receptors (kappa Opioid Receptor)
|4.||(trans)-Isomer 3,4- Dichloro- N- methyl- N- (2- (1- pyrrolidinyl)- cyclohexyl)- benzeneacetamide
|5.||Vasopressin Receptors (Arginine Vasopressin Receptor)
|7.||Messenger RNA (mRNA)
|10.||Arginine Vasopressin (Argipressin)